Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today presented new data from the long-term, open-label KINECT® 4 study demonstrating remission of tardive dyskinesia among the majority of patients treated ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback